BioSpace News Archive

Cidara Therapeutics, Inc. today announced receipt of a $20 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO™ (rezafungin for injection), a novel, once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis.

Catalyst Pharmaceuticals, Inc. today announced that it will release its first-quarter 2023 financial results after market close on Wednesday, May 10, 2023.

Eyenovia, Inc. today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.

Ocular Therapeutix, Inc. today announced that it will report first quarter ended March 31, 2023 financial results after the close on Monday, May 8, 2023.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”) today announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose low-density lipoprotein cholesterol (“LDL-C”) is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

Sphere Fluidics announced its involvement in 3DSecret, a four-year research project funded through the European Innovation Council’s Pathfinder Open 2022, established under Horizon Europe, the EU’s key funding program for research and innovation.

Regenative Labs, a leading human cell, tissue, cellular and tissue-based products manufacturer, has partnered with Dr. Michael Lavor to conduct a prospective study on the efficacy and safety of using umbilical cord tissue allografts for Charcot foot.

Aurinia Pharmaceuticals Inc. announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

Mallinckrodt plc, a global specialty pharmaceutical company, announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.